GE Showcases Breast Tomosynthesis Solution

Article

GE will demonstrate at RSNA 2014 its newly FDA-approved tomosynthesis solution.

GE Healthcare will showcase at RSNA 2014 its new breast imaging 3D tomosynthesis solution, SenoClaire.

SenoClaire, which received FDA approval in August, uses a low-dose short X-ray sweep around the positioned breast with nine exposures acquired with a “step-and-shoot” method, which removes the potential from motion from the tube helping to preserve microcalcification sharpness and avoid image blur, GE said.

The SenoClaire has no increase in dose from a 2D standard mammogram to a 3D view, GE said.

[[{"type":"media","view_mode":"media_crop","fid":"29834","attributes":{"alt":"GE SenoClaire","class":"media-image media-image-right","id":"media_crop_954194364083","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"3114","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 240px; width: 300px; border-width: 0px; border-style: solid; margin: 1px; float: right;","title":"GE SenoClaire","typeof":"foaf:Image"}}]]

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
Leading Breast Radiologists Discuss Rise of Breast Cancer Incidence in Women Under 40
Diagnostic Imaging’s Weekly Scan: August 31 — September 6
Emerging Trends in Breast Imaging: An Interview with Zeeshan Shah, MD
© 2025 MJH Life Sciences

All rights reserved.